PeptiMimesis

PeptiMimesis is a French biotechnology company specializing in the development of therapeutic peptides that target the transmembrane domains of membrane receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Founded as a spin-off from the University of Strasbourg and Inserm, the company utilizes a proprietary platform to disrupt receptor dimerization and signaling, offering a novel approach to treating cancer and inflammatory diseases. Its lead programs focused on targets like CXCR4 and Neuropilin-1 for oncology and immuno-oncology indications. The company's technology aims to overcome the limitations of traditional antibodies and small molecules by specifically interfering with the hydrophobic interactions within the cell membrane. In 2020, PeptiMimesis was acquired by Oncodesign to strengthen its precision medicine and drug discovery capabilities.